The document discusses conducting a project report on studying the problem of new product marketing in the pharmaceutical industry for Cipla Ltd. It provides an introduction and overview of the pharmaceutical sector in India, outlines the scope and limitations of the study, and presents the research methodology including definitions, data collection objectives, hypotheses, literature review, and SWOT analysis.

1. A
PROJECT REPORT ON
TO STUDY THE PROBLEM OF NEW PRODUCT
MARKETING IN PHARMACEUTICALS INDUSTRY
AT
CIPLA LTD
BY
SUBMITTED BY
VIVEK V ALAI
TO
UNIVERSITY OF PUNE,
PUNE
IN PARTIAL FULFILLMENT OF THE
REQUIREMENT FOR THE AWARD OF THE
DEGREE OF MASTER BUSINESS ADMINISTRATION
DR B.V. HIRAY INSTITUTE OF
MANAGEMENT & RESEARCH
MALEGAON
(2012-13)

2. Chapter no. Topic Page no.
I Introduction of
project
Introduction of the
topic
Selection of the
topic
Scope of study
Limitation of study
II Research
methodology
Definition
Data collection on
Objective of study
Hypothesis of study
Review of literature
III Company profile
IV Theory of literature
V Data analysis,
interpretation,&
presentation
VI Observation &
findings
VII Conclusion &
suggestions
VIII Bibliography &
webliography
IX Annexure

3. I. Introduction of
project

4. i. Introduction of topic
OVERVIEW OF PHARMACEUTICAL SECTOR:
Accounting for two percent of the world's pharmaceutical market, the Indian
pharmaceutical sector has an estimated market value of about US $8 billion. It's at
4th rank in terms of total pharmaceutical production and 13th in terms of value. It
is growing at an average rate of 7.2 % and is expected to grow to US $ 12 billion
by 2010.
Over the last two years the pharmaceutical market value has increased to about
US $ 355 million because of the launch of new products. According to an estimate,
3900 new generic products have been launched in the past two years. These have
been by and large launched by big brands in the pharma sector. And in the year
2005 Indian pharmaceutical companies captured around 70% of the domestic
market.
As in the present scenario, only a few people can afford costly drugs, which have
increased price sensitivity in the pharmaceutical market. Now the companies are
trying to capture the market by introducing high quality and low price medicines
and drugs.
With the Product Patent Act, which came into action in January 2005, this industry
is able to attract big MNCs to India. Earlier these big firms had apprehensions in
launching new drugs in the Indian market.
At present, a large number of Indian pharmaceuticals companies are looking for
tie-ups with foreign firms for in-license drugs. GlaxoSmithKline is among the top
choices for the firms that wish to launch their product in India, but do not have any
branch over here.
Contract research and pharmaceutical outsourcing are the new avenues in the
pharmaceutical market. Contract manufacturing is growing at a very fast pace and
is estimated to grow to US $30billion, whereas contract research is estimated to
reach US$6-10 billion.
Indian multinational companies like Dr.Reddy's Lab, Cipla, Ranbaxy, etc
have created awareness about the Indian market prospects in the international
pharmaceutical market. Approvals given by Foods and Drugs Administration
(FDA) and ANDA (Abbreviated New Drug Application)/DMF (Drug Master File)
have played an important role in making India a cost effective and high quality
product manufacturer. Furthermore, the changes that took place in the patent law,

5. change of process patent to product patent, have helped in reducing the risk of
loss for intellectual property.
ii. Scope of study
Scope of Study
 The research helps in dealing with consumers.
 Future researches nay use it as a secondary source of data.
 It provides very useful information about usage behaviors of the cipla respiratory
new product brand.
 The research report could be further used by me in future for advanced research
on the topic.
Limitation
 The area covered by me was very very small that is only Dehradun.
 Consumers were not aware about the entire new products of Sanofi-Aventis
Pharmaceuticals.
 There were not enough parameters or the study material available for the
interpretation of the result so as to reach to a final conclusion.

6. II. Research
methodology

7. SWOT OF SANOFI -AVENTIS
STRENGTH:
Good market position of blockbuster drugs.
Good Indian culture/background
WEAKNESS:
Relative small market share (5 %) compared to Pfizer(10.9%)
Same infrastructure in many countries.
OPPURTUNITY:
Good Market Power.
Economies of scale/ R&D
Synergies in administration.
Many developments cannot be financed without merger.
THREATS:
Diseconomies of scale due to the broader organization and
Complicated communications.